{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:03:44Z","timestamp":1794668624814,"version":"4.9.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.semnuclmed.2025.11.007","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:25:32Z","timestamp":1764624332000},"page":"144-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["New targets of PET imaging for renal cancer"],"prefix":"10.1053","volume":"56","author":[{"given":"Y.","family":"Katayeu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-7687","authenticated-orcid":false,"given":"V.","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.U.","family":"Yesilyurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7213-9417","authenticated-orcid":false,"given":"M.","family":"Al-Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"K.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4380-1629","authenticated-orcid":false,"given":"A.T.","family":"K\u00fcper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1053\/j.semnuclmed.2025.11.007_bib0001","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.3390\/cancers14164059","article-title":"Epidemiology and prevention of renal cell carcinoma","volume":"14","author":"Makino","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.007_bib0002","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0003","series-title":"European Association of Urology (EAU) Guidelines on Renal Cell Carcinoma","author":"Ljungberg","year":"2024"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.007_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035938","article-title":"Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer","volume":"10","author":"Vasudev","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.007_bib0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ejrad.2009.12.023","article-title":"PET\/CT imaging: the incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination","volume":"73","author":"Czernin","year":"2010","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.007_bib0006","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","article-title":"Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma","volume":"12","author":"Wang","year":"2012","journal-title":"Cancer Imaging : Off Publ Int Cancer Imaging Soc"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.007_bib0007","doi-asserted-by":"crossref","first-page":"498","DOI":"10.5152\/dir.2022.21096","article-title":"Role of 18F-FDG PET\/CT for detection of recurrence and metastases in renal cell carcinoma-are we underusing PET\/CT?","volume":"28","author":"Pereira","year":"2022","journal-title":"Diagn Interv Radiol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.007_bib0008","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00259-015-3159-6","article-title":"Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET\/CT","volume":"43","author":"Alongi","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.007_bib0009","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2214\/AJR.19.22467","article-title":"FDG PET\/CT and CT findings of renal cell carcinoma with sarcomatoid differentiation","volume":"215","author":"Zhu","year":"2020","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.007_bib0010","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s11604-025-01761-1","article-title":"Role of 18F-FDG-PET in renal tumors: insights from WHO 2022 classification","volume":"43","author":"Hirota","year":"2025","journal-title":"Jpn J Radiol"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0011","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12885-016-2097-4","article-title":"FDG PET\/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma","volume":"16","author":"Nakaigawa","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.007_bib0012","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1309\/AJCPPPR57HNJMSLZ","article-title":"Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade","volume":"134","author":"Genega","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.007_bib0013","doi-asserted-by":"crossref","first-page":"37","DOI":"10.62347\/VHYY2134","article-title":"CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma","volume":"15","author":"Li","year":"2025","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189120","article-title":"Carbonic anhydrase IX: an atypical target for innovative therapies in cancer","volume":"1879","author":"Ronca","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.007_bib0015","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.155070","article-title":"Immunohistochemical expression of cytochrome P4A11 (CYP4A11), carbonic anhydrase 9 (CAIX) and Ki67 in renal cell carcinoma; diagnostic relevance and relations to clinicopathological parameters","volume":"253","author":"Elfakharany","year":"2024","journal-title":"Pathol Res Pract"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.007_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1309\/AJCPVJDS28KNYZLD","article-title":"Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues","volume":"141","author":"Luong-Player","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"Supplement 1","key":"10.1053\/j.semnuclmed.2025.11.007_bib0018","first-page":"P1113","article-title":"89Zr-DFO-girentuximab PET\/CT imaging can accurately detect clear-cell renal cell carcinoma (ccRCC): results from the ZIRCON phase 3 trial","volume":"64","author":"Calais","year":"2023","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.007_bib0019","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jjco\/hyae075","article-title":"Evaluation of PET\/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP)","volume":"54","author":"Nakaigawa","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0020","unstructured":"UroToday. (2025, October). ESMO 2025: 68Ga-GA-DPI-4452 PET\/CT for staging of patients with clear-cell renal cell carcinoma. UroToday. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2025\/esmo-2025-kidney-cancer\/164095-esmo-2025-68ga-ga-dpi-4452-pet-ct-for-staging-of-patients-with-clear-cell-renal-cell-carcinoma.html"},{"issue":"13","key":"10.1053\/j.semnuclmed.2025.11.007_bib0021","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1007\/s00259-024-06801-y","article-title":"Diagnostic efficacy of [68Ga]Ga-NY104 PET\/CT to identify clear cell renal cell carcinoma","volume":"51","author":"Zhu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.007_bib0022","first-page":"1884","article-title":"Value of [68Ga]Ga-NYM046 PET\/CT, in comparison with 18F-FDG PET\/CT, for diagnosis of clear cell renal cell carcinoma","volume":"65","author":"Lou","year":"2024","journal-title":"J Nucl Med : Off Publ Soc Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.007_bib0023","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2967\/jnumed.123.267175","article-title":"First-in-human safety, imaging, and dosimetry of a carbonic anhydrase IX-targeting peptide, [68Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma","volume":"65","author":"Hofman","year":"2024","journal-title":"J Nucl Med: Off Publ Soc Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.007_bib0024","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00259-024-07007-y","article-title":"Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial","volume":"52","author":"Yang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.007_bib0025","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1007\/s00259-023-06248-7","article-title":"Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.007_bib0026","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","article-title":"Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"69","author":"Muselaers","year":"2016","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0027","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4612","article-title":"STARLITE 2: phase 2 study of nivolumab plus 177lutetium-labeled anti\u2013carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)","volume":"43","author":"Feldman","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0028","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4610","article-title":"Phase 1b\/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC","volume":"42","author":"Jonasch","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.04.003","article-title":"STARLITE 1: phase 1b\/2 study of combined 177Lu-girentuximab plus cabozantinib and nivolumab in treatment-na\u00efve patients with advanced clear-cell renal cell carcinoma","author":"Hasanov","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0030","unstructured":"UroToday. (2025, June 3). ASCO 2025: functional imaging in renal cell carcinoma: Enhancing diagnosis and treatment strategies. UroToday.https:\/\/www.urotoday.com\/conference-highlights\/asco-2025\/asco-2025-kidney-cancer\/160837-asco-2025-functional-imaging-in-renal-cell-carcinoma-enhancing-diagnosis-and-treatment-strategies.html"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.007_bib0031","article-title":"A novel 68Ga\/177Lu-labeled carbonic anhydrase IX (CAIX)-targeting theranostic pair for ccRCC","volume":"66","author":"Yan","year":"2025","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2025.11.007_bib0033","doi-asserted-by":"crossref","unstructured":"Pabst, K. M., Weber, M. M., Laschinsky, C., Sandach, P., Bartel, T., K\u00fcper, A. T., Kessler, L., Trajkovic-Arsic, M., Eckstein, M., Gilman, E., Nader, M., Barbato, F., Podleska, L. E., Hadaschik, B. A., Hamacher, R., Kersting, D., von Ostau, N., von Tresckow, B., Kaelberlah, H. P., Kesch, C., \u2026 Fendler, W. P. (2025). [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial. Lancet Oncol, 26(9), 1204\u20131214. doi:10.1016\/S1470-2045(25)00299-2","DOI":"10.1016\/S1470-2045(25)00299-2"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.007_bib0034","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00259-023-06461-4","article-title":"The role of [68 Ga]Ga-FAPI-04 PET\/CT in renal cell carcinoma: a preliminary study","volume":"51","author":"Civan","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1156","key":"10.1053\/j.semnuclmed.2025.11.007_bib0035","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/bjr\/tqae025","article-title":"A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET\/CT in renal cell carcinoma","volume":"97","author":"Guo","year":"2024","journal-title":"Br J Radiol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.007_bib0036","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1097\/RLU.0000000000004374","article-title":"Superiority of 68Ga-FAPI-04 in delineation of soft tissue and liver metastases in chromophobe renal cell carcinoma for restaging","volume":"47","author":"Xie","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.007_bib0037","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/RLU.0000000000004607","article-title":"68 Ga-FAPI-04 PET\/CT in a small sarcomatoid renal cell carcinoma with widespread metastases","volume":"48","author":"Dong","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.007_bib0038","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2967\/jnumed.124.269002","article-title":"SNMMI procedure standard\/EANM practice guideline for Fibroblast Activation Protein (FAP) PET","volume":"66","author":"Hope","year":"2025","journal-title":"J Nucl Med : Off Publ Soc Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.007_bib0039","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdv289","article-title":"Prospective study evaluating the relative sensitivity of 18F-NaF PET\/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design","volume":"26","author":"Gerety","year":"2015","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.007_bib0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CCO.0000000000000518","article-title":"PET imaging in renal cancer","volume":"31","author":"Lindenberg","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.007_bib0041","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/01.ju.0000158121.49085.ba","article-title":"CD70: a new tumor specific biomarker for renal cell carcinoma","volume":"173","author":"Junker","year":"2005","journal-title":"J Urol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.007_bib0042","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.humpath.2011.10.014","article-title":"CD70 expression patterns in renal cell carcinoma","volume":"43","author":"Jilaveanu","year":"2012","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.007_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100671","article-title":"CD70-targeted cancer theranostics: progress and challenges","volume":"6","author":"Wei","year":"2025","journal-title":"Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.007_bib0044","first-page":"1891","article-title":"CD70-targeted immuno-PET\/CT imaging of clear cell renal cell carcinoma: a translational study","volume":"65","author":"Zhou","year":"2024","journal-title":"J Nucl Med : Off Publ Soc Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.007_bib0045","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s00259-024-06672-3","article-title":"ImmunoPET\/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study","volume":"51","author":"Wu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129982500159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129982500159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:49:32Z","timestamp":1773845372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000129982500159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S000129982500159X"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.007","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New targets of PET imaging for renal cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}